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AbstrACt
Objective To assess the contribution of the severity of 
bronchopulmonary dysplasia (BPD) and the time point 
of its diagnosis to the prediction of neurodevelopmental 
impairment (NDI) at corrected age of 2 years in preterm 
infants.
Design Retrospective cohort study.
setting Level-III perinatal centre.
Patients and outcome measures Infants born in 
2000–2013 with gestational age <30 weeks. BPD was 
defined as FiO
2
 >21% for ≥28 days and its severity 
classified as mild, FiO
2
=21%; moderate, FiO
2
 <30% and 
severe, FiO
2
 ≥30% and/or positive pressure support. We 
applied these criteria at two time points: 36 and 40 weeks’ 
postmenstrual age (PMA). Multivariable regression models 
were used to estimate the association (OR (95% CI)) 
between BPD characteristics and NDI defined as cognitive 
or motor development score <2 SD; severe cerebral palsy; 
deafness and blindness.
results Of 610 (81% of cohort) children assessed at 2 
years, 357 (58%) had BPD and 98 (16%) had NDI. Neither 
FiO
2
 >21% for ≥28 days nor mild or moderate BPD at 
either 36 or 40 weeks’ PMA was associated with NDI, but 
severe BPD was (at 36 weeks’ PMA 5.6 (2.0 to 16.0) and 
at 40 weeks’ PMA 16.6 (4.6 to 59.9)). Infants with severe 
BPD at both 36 and 40 weeks’ PMA had lower mental 
(mean difference −11.4 (−18.5 to −4.3), −25.7(−35.9 to 
−15.5), respectively) and motor (−7.8 (−14.9 to −0.6), 
−20.1(−30.7 to −9.5), respectively),developmental scores 
than infants without BPD.
Conclusion In this cohort, severe BPD was a better 
independent predictor of NDI at 2 years than mild or 
moderate BPD. BPD diagnosed at 40 weeks’ PMA might 
allow better identification of infants at highest risk for NDI.
IntrODuCtIOn
Since its first description in 1967,1 many 
groups have used alternative definitions 
of bronchopulmonary dysplasia (BPD) to 
describe this chronic lung disorder, which 
primarily affects very low birthweight infants. 
Recent evidence suggests that lung dysmat-
uration is a key determinant of the devel-
opment of this condition of the lungs seen 
in extremely premature infants with BPD.2 
The need to quantify BPD severity to enable 
prediction of respiratory outcome for these 
infants led the National Institute of Child 
Health and Human Development (NICHD) 
workshop to introduce a classification in 
2000.3 This definition allows the severity 
of the disease to be classified by oxygen 
dependency and respiratory support at 36 
weeks’ postmenstrual age (PMA) into mild, 
moderate and severe forms. Independent of 
any histopathological correlate, this clinical 
definition has proved useful in the predic-
tion of abnormal pulmonary outcome and 
somatic growth at 2 years of age.4 5 Subse-
quent studies have adopted this classifi-
cation to describe neurodevelopmental 
outcome of infants with BPD, but it remains 
unclear whether BPD severity assessment 
at 36 weeks’ PMA also provides the best 
What is already known on this topic?
 ► Bronchopulmonary dysplasia (BPD) is a chronic 
lung disorder that primarily affects the very low 
birthweight infant.
 ► The current 2000-National Institute of Child Health 
and Human Development  consensus definition 
of BPD allows prediction of abnormal pulmonary 
outcome and somatic growth at 2 years of age.
 ► BPD is defined heterogeneously in the literature.
What this study hopes to add?
 ► Among all forms of bronchopulmonary dysplasia 
(BPD), severe BPD provides the best prediction of 
neurodevelopmental impairment (NDI) at 2 years of 
corrected age.
 ► The assessment of BPD at 40 weeks’ 
postmenstrual age (PMA) might allow better 
identification of infants at high risk for NDI than 
assessment at 36 weeks’ PMA.
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timing of assessment for the prediction of neurological 
outcome.4–9 In fact, despite the 2000-NICHD consensus, 
BPD is defined heterogeneously in the literature, and 
studies describing neurodevelopmental outcome after 
BPD report controversial results.10–12 This study aimed 
to assess the contribution of the severity of BPD and the 
time point of its diagnosis to the prediction of neurode-
velopmental impairment (NDI) at corrected age of 2 
years in preterm infants. We hypothesised that BPD 
severity is an independent risk factor for NDI and that, 
among all criteria, the presence of persistent severe 
BPD at term-equivalent age is the best predictor of 
subsequent neurodevelopmental outcome.
MethODs
study subjects
This is a retrospective cohort study that examined very 
premature liveborn infants with <30 weeks of gestation 
at the Zurich University Hospital, a tertiary perinatal 
centre, from 1 January 2000 to 31 December 2013. 
Exclusion criteria were a priori palliative care in 
delivery room, major congenital anomalies (ie, genetic 
anomaly, syndrome or malformation of a major organ 
system); dead before hospital discharge; transfer to 
another centre within the first day of life and insuf-
ficient documentation. We extracted neonatal and 
follow-up data from the prospective national data-
base of the Swiss Neonatal Network. Specific informa-
tion concerning the severity of BPD according to the 
2000-NICHD consensus3 at 36 and 40 weeks’ PMA was 
extracted from the neonatal charts.
neonatal data
BPD was defined as oxygen supplementation for ≥28 
days of life.3 BPD severity was scored at 36 weeks’ PMA 
according to the 2000-NICHD consensus3 as mild BPD 
(no oxygen supplementation), moderate BPD (oxygen 
supplementation <30%) or severe BPD (oxygen supple-
mentation ≥30% and/or requirement for positive pres-
sure support). BPD severity was also scored at 40 weeks’ 
PMA by the same criteria. Gestational age was defined 
by the best estimate available from prenatal ultrasound 
findings or obstetric measurements based on the last 
menstrual period. Birthweight z-scores were calcu-
lated based on growth curves by Voigt et al.13 Major 
brain lesions were defined as intraventricular haemor-
rhage >grade 2 or cystic periventricular leukomalacia 
on ultrasound examination according to Volpe’s14 and 
de Vries et al’s15 classifications, respectively. Persistent 
ductus arteriosus was defined as a ductus arteriosus 
requiring medical or surgical closure. Retinopathy of 
prematurity, necrotising enterocolitis and neonatal 
sepsis were defined as previously published.8 Socioec-
onomic status was estimated by a validated 12-point 
socioeconomic scale based on maternal education and 
paternal occupation, on which high scores represent 
low socioeconomic class.
neurodevelopmental outcome at 2 years of age
Children were invited to a follow-up at the corrected 
age of 18–24 months in the Child Development Centre 
of the University Children’s Hospital Zurich, where 
experienced developmental paediatricians performed 
a structured neurological examination and a develop-
mental assessment. Following the recommendation of 
the Swiss Neonatal Network, the follow-up examinations 
were based on the Bayley Scales of Infant Development, 
Second Edition, from 2000 to 2013 (BSID-II)16 and then 
on the Bayley Scales of Infant and Toddler Development, 
Third Edition (Bayley-III).17 The Griffiths Mental Devel-
opment Scales-Revised (GMDS)18 were used for a few 
children early in the study. Children with significant disa-
bility precluding completion of the development test were 
assigned a development score of 1 below −3 SD. Cerebral 
palsy was defined according to Rosenbaum et al19 and was 
graded according to the Gross Motor Function Classifica-
tion System (GMFCS) for children aged ≤2 years.20 Vision 
and hearing were assessed by either direct examination 
or caregiver report. NDI was defined as one of following: 
mental or motor development index below 70 (−2SD) on 
the BSID-II; cognitive or motor composite score below 85 
(see below) on the Bayley-III; a global score on the GMDS 
below 76 (−2 SD); cerebral palsy with GMFCS above 1; 
the absence of useful hearing even with aids; blindness 
or only perception of light. According to recent litera-
ture,21–23 Bayley-III scores below 85 were considered as 
equivalent to indices below 70 (−2 SD) in the BSID-II.
statistics
χ2 (or Fisher’s exact test), independent t-test and Mann-
Whitney U tests were used to compare baseline character-
istics between infants with and without BPD. Multivariable 
regression models were used to compare outcome meas-
ures between infants without BPD (reference) and (1) 
infants with BPD, as defined as oxygen supplementation 
for ≥28 days; (2) infants with mild, moderate and severe 
BPD, defined at 36 weeks’ PMA and (3) infants with mild, 
moderate and severe BPD at 40 weeks’ PMA. We adjusted 
models for variables that were significantly unequally 
distributed among groups (see the Results section). 
Two post hoc analyses were performed by adjusting the 
models to include known neonatal predictors of poor 
neurodevelopment (ie, gestational age, sex, necrotising 
enterocolitis, retinopathy of prematurity, major brain 
lesions, sepsis and socioeconomic status) in accordance 
with previous reports8 and by excluding children assessed 
with Bayley-III and GMDS. Associations are given as ORs 
and mean differences (MDs) with 95% CI. In order to 
estimate the calibration and discrimination of the regres-
sion models, we applied the Hosmer and Lemeshow test 
and calculated the area under the receiver operating 
curve, respectively. Finally, we calculated accuracy, sensi-
tivity, specificity and positive and negative predictive 
values for NDI of (1) BPD, (2) BPD severity at 36 weeks’ 
PMA and (3) BPD severity at 40 weeks’ PMA, using the 
group of infants without BPD as reference. We did not 
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impute missing values, because only 4.1% of observations 
were unavailable. SPSS V.21.0 (IBM) was used. Proba-
bility values below 0.05 were considered significant, and 
testing was two-sided.
The study centre was obliged to inform parents about 
the scientific use of anonymised data.
results
study subjects and neonatal data
Among 1270 liveborn infants registered during the study 
period, 516 infants were excluded because of death 
before discharge (n=279), a priori palliative care in 
delivery room (n=179: with gestational age 22 (n=12), 
23 (n=69) and 24 (n=70) weeks, and major congenital 
anomaly (n=28)) transfer to another hospital (n=32), 
major congenital anomalies (n=21) or insufficient 
neonatal documentation (n=5). Among the 754 eligible 
infants, 610 (81%) returned for follow-up (figure 1): 
303 (50%) females, mean (SD, range) gestational age 
27.9 (1.2, 24.4–29.9) weeks and birth weight 1050 (230, 
400–1750) g. Infants lost to follow-up had a higher gesta-
tional age and higher birth weight (both P<0.001), and 
a lower rate of BPD (45% vs 58%, P=0.007) than those 
examined. In the 610 infants examined, BPD was diag-
nosed in 357 (58%). In comparison to infants without 
BPD, infants with BPD presented significant differences 
(table 1): lower gestational age and birthweight z-score, 
Figure 1 Study flow chart. NICU, neonatal intensive care 
unit.
Table 1 Comparison of baseline and neonatal characteristics of infants with and without BPD
All infants n=610
n (%)
Mean (SD)
No BPD n=253
n (%)
Mean (SD)
BPD n=357
n (%)
Mean (SD) P value*
Outborn 50 (8%) 27 (11%) 23 (6%) 0.061
Male gender 307 (50%) 113 (45%) 194 (54%) 0.013
Gestational age (weeks) 27.9 (1.37) 28.5 (1.13) 27.4 (1.32) <0.001
Birth weight (gram) 1030 (250) 1.130 (242) 965 (226) <0.001
z-score 0.27 (0.85) 0.43 (0.80) −0.13 (0.85) 0.015
Small for gestational age† 53 (9%) 21 (8%) 32 (9%) 0.753
Singleton 168 (27%) 64 (26%) 104 (30%) 0.269
Antenatal corticosteroids (completed) 442 (72%) 181 (71%) 261 (73%) 0.669
Chorioamnionitis 143 (23%) 59 (25%) 84 (24%) 0.866
Caesarean delivery 507 (83%) 205 (81%) 302 (84%) 0.247
Umbilical artery pH 7.31 (0.09) 7.31 (0.08) 7.31 (0.09) 0.874
Days of mechanical ventilation 3.4 (6.2) 1.3 (3.3) 3.5 (7.2) 0.001
Surfactant 267 (44%) 76 (30%) 191 (53%) <0.001
Intraventricular haemorrhage >grade 2 44 (7%) 10 (4%) 34 (9%) 0.009
Cystic periventricular leukomalacia 6 (1%) 4 (2%) 2 (1%) 0.206
Retinopathy of prematurity >grade 2 10 (2%) 6 (2%) 14 (4%) 0.315
Sepsis 115 (19%) 25 (10%) 90 (25%) <0.001
Necrotising enterocolitis 22 (4%) 10 (4%) 12 (3%) 0.700
Persistent ductus arteriosus 319 (52%) 99 (39%) 220 (62%) <0.001
Socioeconomic score 5.9 (2.5) 5.9 (2.5) 5.8 (2.5) 0.921
*Comparison between infants with and without BPD: Pearson’s χ2 (or Fisher exact) test (for dichotomous variables) and independent t-test 
and Mann-Whitney U tests (for linear variables).
†Birth weight <10th percentile.
BPD, bronchopulmonary dysplasia.
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longer mechanical ventilation time and a higher rate of 
male sex, surfactant treatment, intraventricular haemor-
rhage higher than grade 2, sepsis and persistent ductus 
arteriosus. At 36 weeks’ PMA, BPD was classified as mild 
in 35%, moderate in 15% and severe in 8% of cases, while 
at 40 weeks’ PMA in 50%, 4% and 3.7% of cases, respec-
tively. Three infants with severe BPD at 36 weeks’ PMA 
but insufficient data at 40 weeks’ PMA needed 22% to 
29% oxygen at discharge from hospital.
neurodevelopmental outcome at 2 years of age
Follow-up assessment was performed at a mean (SD, 
range) corrected age of 23.1 (3.6, 16.5–37.6) months: 
body weight 11.7 (1.8, 8.0–20.0) kg, length 85.6 (5.2, 
68.0–100.0) cm. There was no difference in the mean 
age at follow-up between infants with (23.1 (3.4)) and 
without (23.2 (3.8)) BPD (P=0.770). Of 610 examined 
children, 460 (75%), 109 (18%) and 20 (3%) children 
were assessed with the Bayley-II, Bayley-III and GMDS, 
respectively, while in 21 (4%) children, only part of a 
developmental assessment could be performed. Nine-
ty-eight (16%) children suffered from NDI. Mean (SD) 
mental and motor development indices of Bayley-II 
were 88 (14) and 85 (17), respectively; mean cognitive 
and motor scores of Bayley-III were 99 (15) and 95 (14), 
respectively; mean general quotient of GMDS was 86 
(14). None of the three children without sufficient data 
for scoring BPD severity at 40 weeks’ PMA had NDI.
Association between bPD and its severity defined at 36 and at 
40 weeks’ PMA and nDI
Multivariable logistic regression (adjusted for gestational 
age, sex, birthweight z-score, intraventricular haem-
orrhage >grade 2, persistent ductus arteriosus, days of 
mechanical ventilation, surfactant and sepsis) showed 
that severe BPD was positively associated with NDI at 
age 2 years (OR (95% CI) at 36 weeks’ PMA: 5.6 (2.0 to 
16.0) and at 40 weeks’ PMA: 16.6 (4.6 to 59.9), respec-
tively) (table 2A–C). However, BPD (need for oxygen 
supplementation for ≥28 days of life) and mild and 
moderate BPD at 36 and 40 weeks’ PMA were not. Sensi-
tivity analyses revealed similar results after adjusting for 
known neonatal risk factors for poor neurodevelopment 
(online supplementary table A) and after exclusion of 
children tested with the Bayley-III and GMDS (online 
supplementary table B). The full results of the multivar-
iate models analysing the relationship between BPD and 
NDI are presented in an online supplementary table D.
Mental and psychomotor development indices (BSID-
II) of children with severe BPD were lower than those of 
Table 2 Multivariable association of (A) BPD, defined as oxygen supplementation for ≥28 days of life, and its severity defined 
at (B) 36 weeks’ PMA and (C) 40 weeks’ PMA with NDI at mean (SD) corrected age 23.1 (3.6) months
(A) BPD
No BPD (reference) n=253
BPD
n=357 OR (95% CI) P value
NDI, n (%) 32 (13) 66 (18) 1.5 (0.8 to 2.5) 0.180
Cerebral palsy, n (%) 9 (3) 5 (1.4) 0.4 (0.0 to 2.4) 0.332
Deafness, n (%) 2 (0.8) 3 (0.8) 0.5 (0.0 to 3.7) 0.522
Blindness, n (%) 0 2 (0.6) – NA
(B) 36 weeks’ PMA
No BPD 
(reference)
 n=253
Mild BPD at 
36 PMA 
n=215 OR (95% CI) P value
Moderate 
BPD at 36 
PMA n=91 OR (95% CI) P value
Severe 
BPD at 36 
PMA n=51 OR (95% CI) P value
NDI, n (%) 32 (13) 29 (13) 1.1 (0.6 to 2.1) 0.722 21 (23) 1.5 (0.7 to 3.4) 0.324 16 (31) 5.6 (2.0 to 15.9) 0.001
Cerebral 
palsy, n (%)
9 (3) 3 (1) 0.6 (0.1 to 4.9) 0.680 2 (2) 0.4 (0.0 to 5.2) 0.482 0 – NA
Deafness, n 
(%)
2 (0.8) 1 (0.5) 0.2 (0.0 to 2.9) 0.240 0 – NA 2 (4) 2.0 (0.2 to 25.0) 0.568
Blindness, 
n (%)
0 1 (0.5) – NA 1 (1) – NA 0 – NA
(C) 40 weeks’ PMA
No BPD 
(reference)
 n=253
Mild BPD at 
40 PMA 
n=304 OR (95% CI) P value
Moderate 
BPD at 40 
PMA n=27 OR (95% CI) P value
Severe 
BPD at 40 
PMA n=23 OR (95% CI) P value
NDI, n (%) 32 (13) 46 (15) 1.2 (0.6 to 2.1) 0.599 6 (22) 2.2 (0.6 to 8.1) 0.213 14 (61) 16.6 (4.6 to 59.9) <0.001
Cerebral 
palsy, n (%)
9 (3) 5 (2) 0.4 (0.1 to 2.5) 0.373 0 – NA 0 – NA
Deafness, 
n (%)
2 (0.8) 1 (0) 0.1 (0.0 to 1.9) 0.126 1 (4) 1.5 (0.0 to 34.1) 0.792 1 (4) 0.8 (0.0 to 27.3) 0.933
Blindness, 
n (%)
0 2 (1) – NA 0 – NA 0 – NA
BPD, bronchopulmonary dysplasia; NA, not applicable; NDI, neurodevelopmental impairment; PMA, postmenstrual age. 
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children without BPD when severity was assessed at 36 
and at 40 weeks’ PMA (mean NDI difference −11.4 
(−18.5 to –4.2) and −26.0 (−36.0 to −15.5) and mean 
PDI difference −7.8 (−14.9 to –0.6) and −20.1 (−30.7 to 
−9.5), respectively) (online supplementary table C1). 
BPD was not associated with Bayley-III (online supple-
mentary table C2), rate of cerebral palsy or severe vision 
or hearing problems.
Among all BPD definition criteria, severe BPD at 40 
weeks’ PMA provided the highest specificity (96%), posi-
tive (61%) and negative (87%) predictive values, and 
accuracy (85%) for the prediction of NDI at the time of 
follow-up, while oxygen supplementation for ≥28 days 
of life or at 36 weeks’ PMA provided the best sensitivity 
(67%) (table 3).
DIsCussIOn
This retrospective study aimed to gauge the extent to which 
the severity of BPD and the time of its diagnosis may be used 
to optimise the prediction of neurological development at 
the corrected age of 2 years in preterm infants <30 weeks of 
gestation. The main findings show that, among all forms 
of BPD, severe BPD provides the best prediction of NDI 
and that the assessment of BPD at 40 weeks’ PMA seems to 
better predict NDI than at 36 weeks’ PMA. These two main 
observations are suggestive to confirm our hypothesis, 
and although they do not definitively prove it, they raise 
the question whether the time point for the 2000-NICHD3 
severity-based assessment of BPD at 36 weeks’ PMA might 
be redefined to improve prognosis.
Few studies, including the present one, have adopted 
the severity-based 2000-NICHD consensus definition of 
BPD3 to predict neurodevelopmental outcome. As recently 
reported, a diverse range of definitions of BPD can be 
found in the literature.24 A binary definition of BPD appears 
less informative for the prognosis of neurodevelopmental 
outcome than a severity-based definition. The current 
severity-based definition of BPD was first introduced as a 
practical tool to predict the severity of lung damage, and 
36 weeks’ PMA was identified as the best time point to 
assess severity for the purpose of predicting respiratory 
outcome.25 However, it remains unclear what roles the 
severity of BPD and the timing of the diagnosis play in the 
prediction of neurological development.
The present findings are in agreement with recent liter-
ature26 demonstrating that oxygen supplementation and 
respiratory support at 40 weeks’ PMA are a better predictor 
of neurosensory morbidity at 18–24 months. A severi-
ty-based assessment of BPD of preterm infants at 40 weeks’ 
PMA should be feasible in an outpatient setting, as preterm 
infants have often already been discharged from hospital 
by then.
The BPD incidence observed in our cohort seems to 
be slightly higher than that reported in the literature 
concerning infants born <30 weeks of gestation.24 27 This 
might be explained by a bias in the selection of the study 
subjects; in addition, clinicians’ subjective judgements 
might have influenced the classification of BPD, espe-
cially its mild and moderate forms.2 28 The increase of 
about one-third in the number of infants with mild BPD 
between 36 and 40 weeks’ PMA corroborates this latter 
interpretation. A more objective approach to BPD classi-
fication might have been provided by a room air test to 
identify the objective need of an infant for supplemental 
respiratory support to reach 90% of oxygen saturation 
at a definite PMA. However, our dataset did not reliably 
provide this information.
The negative association between BPD and NDI 
strengthened substantially when infants were diagnosed 
with severe BPD between 36 and 40 weeks’ PMA. This 
provided a higher NDI MD, from 0.8 to 1.7 SD, than 
for infants without BPD. Similar observations have been 
reported previously10 12 but have not exhibited similar 
impact. The lack of association between BPD and the 
developmental scores of the Bayley-III may be explained 
by the small subgroup’s size reducing the power of anal-
ysis. In our study, the number of children affected by 
cerebral palsy, severe hearing and visual disability was not 
sufficient to draw any conclusion on a possible associa-
tion between BPD and these morbidities.
Table 3 Predictive values (95% CI) of BPD for neurodevelopmental impairment at mean (SD) corrected age 23.1 (3.6) months
BPD
Mild BPD at 
36 PMA
Moderate 
BPD at 36 
PMA
Severe BPD 
at 36 PMA
Mild BPD at 
40 PMA
Moderate BPD 
at 40 PMA
Severe BPD 
at 40 PMA
Sensitivity 67% 
(57% to 76%)
47% 
(35% to 61%)
40% 
(26% to 54%)
33% 
(20% to 48%)
59% 
(47% to 70%)
16% 
(6% to 31%)
30% 
(18% to 46%)
Specificity 43% 
(39% to 48%)
54% 
(49% to 59%)
76% 
(71% to 81%)
86% 
(81% to 90%)
46% 
(42% to 50%)
91% 
(87% to 94%)
96% 
(93% to 98%)
Positive 
predictive value
18% 
(16% to 21%)
13% 
(10% to 17%)
23% 
(17% to 31%)
31% 
(22% to 43%)
15% 
(12% to 18%)
22% 
(11% to 40%)
61% 
(42% to 77%)
Negative 
predictive value
87% 
(84% to 90%)
87% 
(84% to 90%)
87% 
(85% to 89%)
87% 
(85% to 89%)
87% 
(84% to 90%)
87% 
(86% to 89%)
87% 
(85% to 89%)
Accuracy 47% 53% 70% 78% 48% 81% 85%
The predictive values of each form of BPD (BPD, mild, moderate, severe) have been calculated with ‘No BPD’ as reference.
BPD, bronchopulmonary dysplasia; PMA, postmenstrual age.
 o
n
 9 O
ctober 2018 by guest. Protected by copyright.
http://bmjpaedsopen.bmj.com/
bmjpo: first published as 10.1136/bmjpo-2017-000165 on 9 January 2018. Downloaded from 
6 Malavolti AM, et al. BMJ Paediatrics Open 2018;2:e000165. doi:10.1136/bmjpo-2017-000165
Open Access
Strength of this study is the size of the cohort, although 
the low prevalence of the severe forms of BPD implies 
wide CIs and high value of negative predictive value. 
Further study strengths are the prospective systematic 
data records concerning neonatal and neurodevelop-
mental variables, and the adjustment of the analyses for 
several confounding factors. The rate of infants lost to 
follow-up of 19% represents a limitation of the study. 
As gestational age and BPD rate were lower and higher, 
respectively, in infants visited at 2 years of corrected age 
than in those lost to follow-up, we might assume that 
we assessed a population sample with high neurodevel-
opmental risk. The other main study limitations are the 
retrospective approach, in which specific characteristics 
of the neonatal respiratory course of the study infants 
have been extracted from their clinical charts; the lack 
of information concerning a room air test for the classi-
fication of BPD severity; and the fact that the indication 
for respiratory support might have been influenced by a 
subjective judgement of the clinicians in charge.
These limitations might have introduced an infor-
mation bias, especially within the group of infants with 
moderate BPD, among whom we observed the largest 
number of reclassifications to mild BPD between 36 and 
40 weeks’ PMA. The inclusion of the various develop-
mental tests used within this cohort represents another 
important limitation, because it might have introduced a 
bias in the classification of outcomes. However, the sensi-
tivity analysis that focused purely on infants tested with 
Bayley-II (the largest group of infants within the cohort) 
supports the study conclusions.
Finally, as no local normative data for Bayley-III is avail-
able in Switzerland yet, we opted to set the cut-off for NDI 
at development scores below 85 and not below 70 for this 
test version. Despite recent literature21–23 in support of this 
choice, we cannot prove the assumption that Bayley-III 
tended to overestimate development in this cohort.
In conclusion, we found that, in this cohort, severe BPD 
was a better independent predictor of NDI at the age of 2 
years than mild or moderate BPD. The diagnosis of severe 
BPD at 40 weeks’ PMA seems to allow better identification 
of infants at high risk of poor neurodevelopment than at 
36 weeks’ PMA. As the generalisability of the present find-
ings is reduced by the study limitations, further prospec-
tive studies are needed to confirm them. In addition to 
the present findings, respiratory outcome data are needed 
to support resetting the BPD definition so as to provide 
higher prognostic value than the current consensus.
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